GRAIL, Inc. (GRAL) Securities Class Action

Commercial stage healthcare company GRAIL focuses on early cancer detection.

The litigation focuses on the propriety of GRAIL’s disclosures about the design of its NHS-Galleri trial (the “trial”) and the likelihood it would meet its primary endpoint – with three consecutive years of follow-up screening, the absolute reduction in the number of late stage (stages 3 and 4) cancer diagnoses.

During the Class Period, GRAIL expressed high confidence in the trial’s design and likely outcomes. They consistently stated that the three-year duration was specifically chosen to demonstrate a statistically significant reduction in combined stage 3 and 4 cancers.

The complaint alleges that GRAIL misled investors by creating the false impression that it possessed reliable information supportive of the probability of the trial achieving its primary endpoint.  The complaint further alleges that GRAIL’s expressed optimism was unrealistic because, unknown to investors, the company had information suggesting that three years would be insufficient to support the trial’s achievement of the primary endpoint.

 Investors learned the truth on February 19, 2026. That day, the defendants announced that the trial failed to achieve its primary endpoint. Of significant concern was the admission that “we probably should have allowed for a longer follow-up period.”

The market quickly reacted, sending the price of GRAIL shares down over 50% the next day.

FREQUENTLY ASKED QUESTIONS ABOUT THE CASE

What is the GRAL investigation about?

We are focused on when GRAIL and its management knew that the need for a longer follow-up period diverged from the touted three-year duration.

WHAT SHOULD I DO?

I worked at GRAL. What should I do?

If you were an employee of GRAL, you may have valuable information that could be relevant to the investigation. Hagens Berman is one of the nation’s top whistleblower law firms, and has successfully represented many individuals who come forward with information regarding corporate malfeasance. Under the new SEC Whistleblower program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC. For more information, contact Reed Kathrein at 844-916-0895 or [email protected].

There are multiple law firms participating, do I need to contact all of them?

No, you do not need to contact all participating law firms. Generally, class-action investigations and lawsuits are consolidated into a single case to streamline the legal process, and attorneys from only a few law firms are selected to serve in a leadership role on the consolidated case. Hagens Berman has a proven track record of being appointed to leadership roles in complex, multidistrict litigation regarding investor fraud and other consumer rights issues, and your claim will be handled by attorneys who have helped secure approximately $325 billion in class-action settlements on behalf of individuals who have suffered due to corporate malfeasance and the wrongdoing of other powerful institutions.

AM I ELIGIBLE?

What is the threshold amount to be eligible? What are “substantial” losses?

The threshold amount and the definition of "substantial" losses may vary depending on a number of factors specific to the case, including the size of the company, market cap, shares outstanding and who holds them and the damages alleged by the fraud. In general, to be eligible to participate in a class-action lawsuit, you must be able to demonstrate that you suffered financial losses as a result of the alleged wrongdoing and that your losses meet the criteria set by the court or law firm. Fill out the form and submit your losses.

CAN I PARTICIPATE?

Am I affected? What do I need to do to participate?

If you were an investor in GRAL, you may be affected and eligible to participate in the case. To determine your eligibility and potential involvement, fill out the form and submit your losses.

Can any GRAL investor participate?

In most class-action investigations and cases, any investor who meets the eligibility criteria, including purchasing the shares during the relevant period, can participate, regardless of the size of their investment. Fill out the form to find out your rights.

I bought on a non-U.S. Exchange. Can I participate?

No. This investigation only covers shares bought on a U.S. exchange, i.e. NASDAQ or NYSE. Fill out the form to find out your rights.

Am I included if I still hold my shares, or do I need to sell to participate?

Participation is based on purchasing shares during the relevant period, rather than your current holdings. Accordingly, you do not need to sell to participate. Fill out the form to find out your rights.